Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: Metadata lists "Inotiv, Inc." but the filing text identifies the registrant as Bioanalytical Systems, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2001
Business Overview: The Company provides products and research services globally to pharmaceutical and biotechnology firms to support drug development. Operations are divided into two segments: analytical services (chemistry support) and products (liquid chromatography, electrochemical, and physiological monitoring devices).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2001 | Six Months Ended Mar 31, 2001 | Balance Sheet (Mar 31, 2001) |
|---|---|---|---|
| Total Revenue | $6,842 | $12,268 | - |
| Net Income | $582 | $777 | - |
| Operating Income | $1,119 | $1,610 | - |
| Gross Margin | 50.7% | 48.0% | - |
| Cash and Equivalents | - | - | $325 |
| Working Capital | - | - | $2,092 |
| Debt (Current + Long-Term) | - | - | $5,647 |
| EPS (Diluted) | $0.13 | $0.17 | - |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 67.3% for the three months ended March 31, 2001, compared to the same period in 2000. This was driven by a 63.5% increase in service revenue (due to additional bioanalytical contracts) and a 74.0% increase in product revenue (driven by Culex automated blood sampling devices).
- Profitability Turnaround: The Company reported a net income of $582,000 for the quarter, a significant improvement from a net loss of $427,000 in the prior year quarter. Operating income swung from a loss of $525,000 to a profit of $1,119,000.
- Margin Expansion: Gross margin improved significantly. Cost of service revenue as a percentage of revenue dropped from 83.0% to 58.9%, and cost of product revenue dropped from 35.5% to 33.3%.
- Cash Flow: Net cash provided by operating activities turned positive at $937,000 for the six months ended March 31, 2001, compared to a use of $1,236,000 in the prior year period.
- Expense Increases: General and administrative expenses rose 36.5% quarter-over-quarter due to increased staffing in the preclinical services unit.
Outlook, Risks, and Contingencies
- Liquidity: Management believes cash generated from operations and the existing $3.5 million line of credit (renewed to expire April 1, 2002) are sufficient to fund working capital and capital expenditure requirements.
- Debt Obligations: The Company maintains a working capital line of credit with $2.01 million outstanding and a $3.5 million commercial mortgage with a balloon payment of $2.35 million due in June 2004.
- Legal Proceedings: A patent infringement lawsuit filed by CMA Microdialysis Holding A.B. regarding microdialysis probes was settled in the quarter ended December 31, 2000, for an immaterial amount.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks associated with strategic plans, future profitability, and industry trends.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 67% revenue growth, specifically the reliance on new bioanalytical contracts and Culex device sales.
- Accounts Receivable: Accounts receivable increased by $1.68 million ($1.7M) during the six-month period; verify collection trends and days sales outstanding (DSO).
- Debt Covenants: Confirm compliance with financial ratios required by the bank line of credit and mortgage agreements.
- Capital Expenditures: Review the $618,000 in capital expenditures for the six months to ensure alignment with expansion plans for operating facilities and laboratory equipment.
- Tax Rate: Note the effective tax rate increased to 41.3% (from 35.0%) due to nondeductible foreign losses; assess the impact of future foreign operations on tax efficiency.